You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
NEW YORK – Bayer said on Tuesday that it will pay Systems Oncology $25 million upfront for rights to a compound in preclinical development for estrogen receptor (ER)-positive, metastatic breast cancer.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?Register for Free.